KROS
Keros Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-19/100
Last price
11.01
▼ 0.51 (4.43%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
11.56
Prev close
11.52
Day high
11.63
Day low
10.95
Volume
185.32K
Market cap
$218.30M
P/E (TTM)
—
52W range
9.69 – 22.55
Day trading desk
Gap from prior close
+0.35%
Prior close 11.52
VWAP
11.12
-1.00% from price
Relative volume
1.74×
Unusually busy
Session range
6.21%
10.95 – 11.63
Position in range
9%
Near session low
ATR (14D)
0.49
4.48% of price
Prior day high
11.56
PDH
Prior day low
11.07
PDL
Bid / ask spread
—
Quote not published
Session volume
345.99K
Avg 198.98K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.61%
-3.6%
1M
-2.74%
-3.9%
3M
-5.66%
-10.2%
6M
-10.05%
-28.2%
YTD
-45.92%
-60.2%
1Y
-30.93%
-47.3%
3Y
-65.46%
-147.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on KROS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+36.24K
Net buying
Buy transactions
11
54.50K shares
Sell transactions
8
18.25K shares
Net transactions
+19
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
785.95K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | NEWTON CHARLES W. Director |
SELL | 551 | $5.67K | Direct |
| Aug 18, 26 | LERNER LORENA RAQUEL PH.D. Officer |
SELL | 3.57K | $36.72K | Direct |
| Aug 18, 26 | CHO ESTHER Officer |
SELL | 4.49K | $46.15K | Direct |
| Aug 17, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 1.00K | $10.27K | Direct |
| Jul 15, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 1.00K | $10.61K | Direct |
| Jul 1, 26 | PRENER ANNE Director |
STOCK | 13.79K | $0 | Direct |
| Jun 15, 26 | BIENAIME JEAN-JACQUES Director |
BUY | 1.00K | $10.19K | Direct |
| Jun 11, 26 | NEWTON CHARLES W. Director |
SELL | 550 | $5.52K | Direct |
| Jun 4, 26 | SETH ALPNA Director |
SELL | 2.63K | $28.14K | Direct |
| Jun 4, 26 | FARZAN NIMA Director |
SELL | 2.63K | $28.17K | Direct |
| Jun 4, 26 | KNOWLES JULIUS Director |
SELL | 2.63K | $28.17K | Direct |
| Jun 3, 26 | BIENAIME JEAN-JACQUES Director |
STOCK | 7.14K | $0 | Direct |
| Jun 3, 26 | GRAY MARY ANN Director |
STOCK | 7.14K | $0 | Direct |
| Jun 3, 26 | SETH ALPNA Director |
STOCK | 7.14K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHO ESTHER |
Officer | 35.77K | Sale |
CHYUNG YUNG H. M.D. |
Officer | 44.00K | Stock Award(Grant) |
GORDON CARL L |
Director | 1.02M | Stock Award(Grant) |
KARIV TOMER |
Director and Beneficial Owner of more than 10% of a Class of Security | 4.64M | Stock Award(Grant) |
KNOWLES JULIUS |
Director | 263.24K | Sale |
LERNER LORENA RAQUEL PH.D. |
Officer | 27.56K | Sale |
NUSSBAUM RAN |
Director and Beneficial Owner of more than 10% of a Class of Security | 4.64M | Stock Award(Grant) |
REGNANTE KEITH C |
Chief Financial Officer | 39.26K | Sale |
ROVALDI CHRISTOPHER |
Chief Operating Officer | 60.00K | Stock Award(Grant) |
SEEHRA JASBIR |
Chief Executive Officer | 440.71K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$218.30M
Enterprise value$-23.58M
Revenue (TTM)$15.01M
Gross profit$-58.34M
EBITDA$-96.87M
Net income$-83.16M
EPS (TTM)$-3.07
Free cash flow$-27.17M
Total cash$257.61M
Total debt$15.72M
Book value / share$13.23
Shares outstanding19.83M
Float17.77M
Short % of float7.79%
Dividend yield0.00%
Beta (5Y)1.12
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.66
PEG ratio—
Price / sales—
Price / book0.83
EV / revenue-1.57
EV / EBITDA0.24
Gross margin0.00%
Operating margin-655.84%
Profit margin0.00%
Return on equity-17.16%
Return on assets-11.78%
Debt / equity5.99
Current ratio21.96
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $244.06M | $3.55M | $151.00K | $0 | — | +6,775.0% |
| Operating revenue | $244.06M | $3.55M | $151.00K | $0 | — | +6,775.0% |
| Research & development | $129.64M | $173.63M | $135.26M | $87.27M | — | -25.3% |
| Selling, general & admin | $46.85M | $40.75M | $34.83M | $27.52M | — | +15.0% |
| Total operating expense | $176.49M | $213.15M | $167.69M | $107.71M | — | -17.2% |
| Operating income | $67.57M | -$209.59M | -$167.54M | -$107.71M | — | +132.2% |
| Net interest income | — | $0 | $0 | -$1.00K | -$4.00K | — |
| Pre-tax income | $91.90M | -$187.05M | -$152.99M | -$104.68M | — | +149.1% |
| Tax provision | $4.88M | $300.00K | $0 | $0 | — | +1,527.7% |
| Net income | $87.01M | -$187.35M | -$152.99M | -$104.68M | — | +146.4% |
| Net income to common | $87.01M | -$187.35M | -$152.99M | -$104.68M | — | +146.4% |
| Basic EPS | 2.34 | -5.00 | -5.20 | -4.15 | — | +146.8% |
| Diluted EPS | 2.30 | -5.00 | -5.20 | -4.15 | — | +146.0% |
| EBIT | $67.57M | -$209.59M | -$152.99M | -$104.68M | — | +132.2% |
| EBITDA | $69.08M | -$208.37M | -$152.18M | -$104.00M | — | +133.2% |
| Basic shares | 37.22M | 37.44M | 29.45M | 23.44M | — | -0.6% |
| Diluted shares | 37.86M | 37.44M | 29.45M | 23.44M | — | +1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $287.42M | $559.93M | $331.15M | $279.05M | -48.7% |
| Cash & short-term investments | $287.42M | $559.93M | $331.15M | $279.05M | -48.7% |
| Accounts receivable | $3.57M | $2.74M | $143.00K | $0 | +30.1% |
| Total current assets | $315.43M | $588.89M | $347.29M | $285.77M | -46.4% |
| Property, plant & equipment | $21.14M | $23.49M | $19.47M | $17.57M | -10.0% |
| Total assets | $338.02M | $615.89M | $370.02M | $306.78M | -45.1% |
| Total current liabilities | $20.41M | $27.45M | $24.37M | $16.55M | -25.6% |
| Total debt | $16.88M | $18.86M | $14.44M | $13.27M | -10.5% |
| Total liabilities | $34.89M | $44.33M | $37.81M | $29.36M | -21.3% |
| Retained earnings | -$481.76M | -$568.78M | -$381.43M | -$228.43M | +15.3% |
| Shareholder equity | $303.13M | $571.55M | $332.21M | $277.42M | -47.0% |
| Working capital | $295.02M | $561.44M | $322.92M | $269.22M | -47.5% |
| Net tangible assets | $303.13M | $571.55M | $332.21M | $277.42M | -47.0% |
| Shares issued | 40.67M | 40.55M | 31.84M | 27.54M | +0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $87.01M | -$187.35M | -$152.99M | -$104.68M | +146.4% |
| Depreciation & amortisation | $1.51M | $1.23M | $815.00K | $674.00K | +22.8% |
| Stock-based compensation | $28.70M | $34.87M | $28.76M | $18.68M | -17.7% |
| Change in working capital | -$12.11M | -$11.44M | -$2.65M | $14.31M | -5.9% |
| Operating cash flow | $107.50M | -$160.87M | -$124.51M | -$70.06M | +166.8% |
| Capital expenditure | -$1.55M | -$1.93M | -$2.46M | -$1.24M | +19.7% |
| Investing cash flow | -$1.55M | -$1.93M | -$2.46M | -$1.24M | +19.7% |
| Share buybacks | -$375.00M | $0 | — | — | — |
| Financing cash flow | -$378.47M | $391.82M | $178.96M | $120.31M | -196.6% |
| Free cash flow | $105.95M | -$162.80M | -$126.97M | -$71.30M | +165.1% |
| End cash position | $288.86M | $561.38M | $332.36M | $280.38M | -48.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $367.00K | $385.00K | $14.26M | $18.17M | -100.0% |
| Operating revenue | $0 | $367.00K | $385.00K | $14.26M | $18.17M | -100.0% |
| Research & development | $22.33M | $16.10M | $17.91M | $19.52M | $43.50M | +38.7% |
| Selling, general & admin | $8.61M | $10.15M | $11.74M | $10.13M | $14.48M | -15.2% |
| Total operating expense | $30.94M | $26.24M | $29.66M | $29.65M | $57.98M | +17.9% |
| Operating income | -$30.94M | -$25.88M | -$29.27M | -$15.38M | -$39.82M | -19.6% |
| Pre-tax income | -$28.71M | -$23.71M | -$24.98M | -$8.70M | -$32.92M | -21.1% |
| Tax provision | $0 | $0 | -$1.51M | -$1.42M | -$2.22M | — |
| Net income | -$28.71M | -$23.71M | -$23.46M | -$7.28M | -$30.70M | -21.1% |
| Net income to common | -$28.71M | -$23.71M | -$23.46M | -$7.28M | -$30.70M | -21.1% |
| Basic EPS | -1.45 | -1.21 | -0.86 | -0.18 | -0.76 | -19.8% |
| Diluted EPS | -1.45 | -1.21 | -0.86 | -0.18 | -0.76 | -19.8% |
| EBIT | -$30.94M | -$25.88M | -$29.27M | -$15.38M | -$39.82M | -19.6% |
| EBITDA | -$30.54M | -$25.47M | -$28.87M | -$14.99M | -$39.45M | -19.9% |
| Basic shares | 19.80M | 19.63M | 27.20M | 40.62M | 40.61M | +0.9% |
| Diluted shares | 19.80M | 19.63M | 27.20M | 40.62M | 40.61M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $257.61M | $281.50M | $287.42M | $693.47M | $690.22M | -8.5% |
| Cash & short-term investments | $257.61M | $281.50M | $287.42M | $693.47M | $690.22M | -8.5% |
| Accounts receivable | $0 | $400.00K | $3.57M | $3.49M | $15.82M | -100.0% |
| Total current assets | $266.88M | $290.68M | $315.43M | $719.31M | $732.81M | -8.2% |
| Property, plant & equipment | $19.27M | $20.17M | $21.14M | $22.03M | $22.91M | -4.5% |
| Total assets | $287.60M | $312.29M | $338.02M | $742.78M | $757.16M | -7.9% |
| Total current liabilities | $12.15M | $12.85M | $20.41M | $24.09M | $34.71M | -5.4% |
| Total debt | $15.72M | $16.31M | $16.88M | $17.43M | $17.95M | -3.6% |
| Total liabilities | $25.28M | $26.66M | $34.89M | $39.20M | $50.43M | -5.2% |
| Retained earnings | -$534.18M | -$505.47M | -$481.76M | -$458.30M | -$451.02M | -5.7% |
| Shareholder equity | $262.32M | $285.63M | $303.13M | $703.58M | $706.73M | -8.2% |
| Working capital | $254.73M | $277.82M | $295.02M | $695.22M | $698.10M | -8.3% |
| Net tangible assets | $262.32M | $285.63M | $303.13M | $703.58M | $706.73M | -8.2% |
| Shares issued | 19.83M | 40.86M | 40.67M | 40.63M | 40.62M | -51.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$28.71M | -$23.71M | -$23.46M | -$7.28M | -$30.70M | -21.1% |
| Depreciation & amortisation | $402.00K | $403.00K | $400.00K | $395.00K | $370.00K | -0.2% |
| Stock-based compensation | $5.38M | $6.20M | $7.30M | $3.99M | $8.54M | -13.3% |
| Change in working capital | $1.86M | $12.94M | -$12.16M | $5.54M | -$8.42M | -85.6% |
| Operating cash flow | -$20.42M | -$3.53M | -$27.29M | $3.25M | -$29.62M | -478.7% |
| Capital expenditure | -$155.00K | -$73.00K | -$134.00K | -$132.00K | -$720.00K | -112.3% |
| Investing cash flow | -$155.00K | -$73.00K | -$134.00K | -$132.00K | -$720.00K | -112.3% |
| Financing cash flow | -$3.31M | -$2.32M | -$378.63M | $140.00K | $17.00K | -43.1% |
| Free cash flow | -$20.58M | -$3.60M | -$27.43M | $3.12M | -$30.34M | -471.2% |
| End cash position | $259.06M | $282.95M | $288.86M | $694.92M | $691.66M | -8.4% |
Options analytics
Put / call volume
1.67
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
10.00
-9.2% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
6
Contracts, this expiry
Put volume
10
Contracts, this expiry
Heaviest call OI
10.00
0 contracts
Heaviest put OI
10.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.24 | -1.45 | -16.8% |
| Mar 2026 | -0.92 | -1.21 | -31.5% |
| Dec 2025 | -0.45 | -0.86 | -90.4% |
| Sep 2025 | -0.92 | -0.18 | +80.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.86 | 4 | $13.89M | -2.6% |
| Next quarter | -1.78 | 5 | $478.57K | +24.3% |
| Current year | -5.22 | 5 | $15.57M | -93.6% |
| Next year | -6.62 | 5 | $13.73M | -11.8% |
Analyst targets & ownership
Mean target$19.83
High target$25.00
Low target$16.00
Implied upside80.14%
Analyst count6
ConsensusBUY
Strong buy / Buy0 / 4
Hold3
Sell / Strong sell0 / 0
Held by insiders3.96%
Held by institutions95.23%
Institutions holding189
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.38
-3.27% from price
SMA 20
11.31
-2.68% from price
SMA 50
10.98
+0.27% from price
SMA 100
10.86
+1.41% from price
SMA 200
12.82
-14.13% from price
EMA 12
11.32
-2.72% from price
EMA 26
11.25
-2.11% from price
EMA 50
11.13
-1.11% from price
RSI (14)
46.0
Neutral
MACD (12,26,9)
0.07
Hist -0.04
ATR (14)
0.49
4.48% of price
Realised vol 30D
41.6%
Annualised
Bollinger upper
11.78
20, 2σ
Bollinger lower
10.85
20, 2σ
50 / 200 cross
Death
10.98 vs 12.82
Trend bias
Below 200
-14.13%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.09
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
41.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-54.6%
Peak to trough
Max drawdown 5Y
-86.5%
Peak to trough
ATR 14
0.49
4.48% of price
Beta (reported)
1.12
5Y monthly, from filing
Short interest
Shares short
1.34M
Prior 1.15M
Change vs prior
+16.9%
Shorts adding
% of float
7.79%
Normal
% of shares out
6.77%
Against total outstanding
Days to cover
7.7
Crowded exit
Float
17.77M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Aug 4, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Mar 5, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Nov 28, 25 | B of A Securities | MAINTAINED | Neutral | Neutral |
| Nov 12, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Nov 11, 25 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Nov 6, 25 | Wedbush | MAINTAINED | Neutral | Neutral |
| Aug 8, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 10, 25 | B of A Securities | DOWNGRADE | Buy | Neutral |
| May 30, 25 | Wedbush | MAINTAINED | Neutral | Neutral |
| May 12, 25 | Scotiabank | MAINTAINED | Sector Outperform | Sector Outperform |
| May 8, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-09-28
Separately filed delaying amendment under Securities Act Rule 473 to delay effectiveness of a 1933 Act registration statement
DEL AM · 2026-09-11
Offering Registrations
S-3 · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-07-22
Headlines
Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
MT Newswires · 8d ago
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Zacks · 8d ago
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
GlobeNewswire · 8d ago
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
GlobeNewswire · 9d ago
Keros Therapeutics Approves $5 Million Share Buyback
MT Newswires · 28d ago
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
GlobeNewswire · 28d ago
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Zacks · 35d ago
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Zacks · 44d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.